Filing Details
- Accession Number:
- 0001209191-22-051671
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-30 17:17:53
- Reporting Period:
- 2022-08-16
- Accepted Time:
- 2022-09-30 17:17:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1087294 | Cumberland Pharmaceuticals Inc | CPIX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1684087 | Caroline Young | 2525 West End Avenue Suite 950 Nashville TN 37203 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-08-16 | 20 | $2.35 | 17,702 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-17 | 20 | $2.31 | 17,722 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-18 | 20 | $2.23 | 17,742 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-19 | 20 | $2.35 | 17,762 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-22 | 20 | $2.51 | 17,782 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-23 | 20 | $2.59 | 17,802 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-24 | 20 | $2.59 | 17,822 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-25 | 20 | $2.62 | 17,842 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-26 | 20 | $2.55 | 17,862 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-29 | 22 | $2.44 | 17,884 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-30 | 22 | $2.38 | 17,906 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-08-31 | 22 | $2.36 | 17,928 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-01 | 22 | $2.39 | 17,950 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-02 | 22 | $2.42 | 17,972 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-06 | 22 | $2.15 | 17,994 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-07 | 22 | $2.24 | 18,016 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-08 | 22 | $2.22 | 18,038 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-09 | 20 | $2.21 | 18,058 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-12 | 22 | $2.46 | 18,080 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-13 | 22 | $2.45 | 18,102 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-14 | 22 | $2.51 | 18,124 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-15 | 22 | $2.47 | 18,146 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-16 | 22 | $2.49 | 18,168 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-19 | 20 | $2.56 | 18,188 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-20 | 20 | $2.54 | 18,208 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-21 | 20 | $2.59 | 18,228 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-22 | 20 | $2.51 | 18,248 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-23 | 20 | $2.55 | 18,268 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-26 | 20 | $2.49 | 18,288 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-09-27 | 20 | $2.57 | 18,308 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.